[
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-1",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#definitiongeneral266881",
    "clean_content": "Definition / general\n\n* Acquired autoimmune bleeding disorder characterized by isolated thrombocytopenia (peripheral blood platelet count < 100 × 109/L) ([Blood 2009;113:2386](19005182))* Mixed cell mediated and antibody mediated: abnormal T cell responses resulting in platelet destruction primarily in the spleen, mainly due to antiplatelet autoantibodies ([J Clin Med 2017;6:16](28208757))"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-2",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#essentialfeatures266882",
    "clean_content": "Essential features\n\n* Immune thrombocytopenia (ITP) is a diagnosis of exclusion with an isolated thrombocytopenia of < 100 × 109/L ([Blood 2009;113:2386](19005182))* Affected sites predominantly include skin and mucous membranes (petechiae, wet / dry purpura) and spleen (primary site of platelet clearance)* Impairment in CD4+ T regulatory cells and dendritic cells leads to the initiation and perpetuation of ITP ([Curr Opin Hematol 2020;27:423](32868673))* Thrombocytopenia is due to IgG antiplatelet autoantibodies (principle mechanism of antibody mediated platelet phagocytosis), cytotoxic CD8+ T cells and impaired megakaryocyte function ([J Clin Med 2017;6:16](28208757))* Primary diagnostic tests include complete blood counts, peripheral blood smear and testing to exclude HIV and hepatitis C virus; antiplatelet antibody testing is among the supportive tests that may be performed ([UpToDate: Immune Thrombocytopenia (ITP) in Adults - Clinical Manifestations and Diagnosis [Accessed 16 February 2021]](https://www.uptodate.com/contents/immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis))"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-3",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#terminology266883",
    "clean_content": "Terminology\n\n* Formerly known as idiopathic thrombocytopenic purpura"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-4",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#icdcoding266884",
    "clean_content": "ICD coding\n\n* ICD-10: [D69.3](https://www.icd10data.com/ICD10CM/Codes/D50-D89/D65-D69/D69-/D69.3) - Immune thrombocytopenic purpura"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-5",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#epidemiology266885",
    "clean_content": "Epidemiology\n\n* Annual incidence: ~1 - 6 per 100,000 adults ([Am J Hematol 2012;87:848](22674643))* Prevalence: ~12 per 100,000 in adults and 8 per 100,000 in children ([Am J Hematol 2012;87:848](22674643))* Increased incidence with increasing age ([Am J Hematol 2012;87:848](22674643), [Br J Haematol 2009;145:235](19245432))* Incidence: M = F when > 60 years of age* Childhood ITP is a clinically distinct condition from adult ITP with a higher likelihood of spontaneous remission"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-6",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#sites266886",
    "clean_content": "Sites\n\n* Skin:\n  + Petechiae (flat, red, discrete lesions that do not blanch under pressure), often lower legs in ambulatory patients or sacral area in recumbent patients+ Dry purpura (coalescence of petechiae, nonpalpable)* Mucous membranes (such as oral mucosa):\n    + Wet purpura (hemorrhagic blisters)* Severe bleeding:\n      + Affects a minority of patients ([J Thromb Haemost 2015;13:457](25495497))+ Associated with marked thrombocytopenia and new diagnosis of ITP+ Extensive mucosal bleeding often present+ Intracranial hemorrhage uncommon* Spleen: primary site of platelet clearance in most patients* Liver, bone marrow or lymph nodes: may also be sites of platelet clearance"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-7",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#pathophysiology266887",
    "clean_content": "Pathophysiology\n\n* Impairment in CD4+ T regulatory cells and dendritic cells leads to the initiation and perpetuation of ITP\n  + Decreased CD4+ CD25+ FOXP3+ T regulatory cell levels and function in patients with active disease ([Curr Opin Hematol 2020;27:423](32868673))+ Also dendritic cells and myeloid derived suppressor cells have been described to be impaired in ITP ([Curr Opin Hematol 2020;27:423](32868673), [Blood 2016;127:1587](26744458))* Thrombocytopenia due to:\n    + IgG antiplatelet autoantibodies (principle mechanism) bind to platelet surface antigens (such as glycoprotein [GP] αIIbβ3 [GPIIbIIIA] and GPIb-IX-V)+ Platelets with bound autoantibodies are subsequently recognized by macrophages bearing Fcγ receptors (FcγRs), resulting in antibody mediated platelet phagocytosis and destruction primarily in the spleen ([Haematologica 2021;106:250](32107327))+ Cytotoxic CD8+ T cells may directly lyse platelets ([Nat Med 2003;9:1123](12937414))+ Impaired megakaryocyte function resulting in impaired platelet production due to targeting by antiplatelet autoantibodies or CD8+ T cells in the bone marrow ([Haematologica 2015;100:623](25682608), [Blood 2008;112:1078](18519809))"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-8",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#diagnosis266891",
    "clean_content": "Diagnosis\n\n* ITP is a diagnosis of exclusion; an isolated thrombocytopenia is present (peripheral blood platelet count < 100 × 109/L) without anemia or leukopenia and without another apparent cause of thrombocytopenia"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-9",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#laboratory266892",
    "clean_content": "Laboratory\n\n* Complete blood counts, peripheral blood smear: to confirm thrombocytopenia and to exclude platelet morphology abnormalities (e.g. lack of platelet granules or uniformly large or small platelets) suggestive of hereditary platelet disorders or myelodysplasia* HIV and hepatitis C virus testing: may explain the thrombocytopenia and treating the underlying infection might improve the platelet count* Additional testing for patients with suspected ITP may include:\n      + *Helicobacter pylori* testing: in case of gastrointestinal symptoms suggestive of infection due to association between ITP and *H. pylori* infection+ Bone marrow investigation: not required for typical presentation\n          - Normal or increased number of megakaryocytes- In some patients, a shift towards younger megakaryocytes with hypolobation or lesser degrees of nuclear polyploidy and less evidence of platelet production+ Vitamin B12 and folate levels: required for hematopoiesis and their deficiency may present with mild thrombocytopenia+ Coagulation studies: to investigate and treat other potential causes of thrombocytopenia (e.g. liver disease) and bleeding (e.g. vitamin K deficiency)+ Immunologic studies (e.g. testing for antinuclear antibodies or quantitative immunoglobulin levels to identify underlying common variable immune deficiency)+ Antiplatelet antibody testing (not always detectable)* Reference: [Curr Opin Hematol 2020;27:423](32868673), [UpToDate: Immune Thrombocytopenia (ITP) in Adults - Clinical Manifestations and Diagnosis [Accessed 16 February 2021]](https://www.uptodate.com/contents/immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis)"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-10",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#prognosticfactors266895",
    "clean_content": "Prognostic factors\n\n* Adult ITP: majority stable, safe platelet count due to spontaneous remission (up to 10%) or therapy, often within first 6 months ([Br J Haematol 2003;122:966](12956768))* Childhood ITP: spontaneous remission (up to 50%) after months or even years of chronic ITP"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-11",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#casereports266896",
    "clean_content": "Case reports\n\n* 3 year old boy and girl with intravenous immunoglobulin refractory ITP receiving chemotherapy for high risk neuroblastoma ([J Pediatr Hematol Oncol 2019;41:e257](29683946))* 41 year old woman with anti-GPVI mediated ITP ([Res Pract Thromb Haemost 2017;1:291](30046699))* 48 year old man critically ill with COVID-19 ([Int J Infect Dis 2020;99:269](32771636))* 65 and 71 year old men presenting with lethal diffuse alveolar hemorrhage ([Case Rep Hematol 2019;2019:5170282](31281686))"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-12",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#treatment266897",
    "clean_content": "Treatment\n\n* First line includes corticosteroids, intravenous immunoglobulin and anti-D immunoglobulin* Subsequent treatments include rituximab, splenectomy or thrombopoietin receptor agonists* Treatment goals: maintaining platelet counts > 20 - 30 × 109/L for at least symptomatic patients ([Blood Adv 2019;3:3780](31770441))"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-13",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Clinical images",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#clinicalimages266898",
    "clean_content": "Clinical images\n\nImages hosted on other servers:  \n\n[![](https://www.pathologyoutlines.com/thumb/spleenITP_wiki01.jpg)](https://en.wikipedia.org/wiki/Immune_thrombocytopenic_purpura#/media/File:Purpura.jpg)\n\nPetechiae or small bruise-like markings"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-14",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#microscopichistologicdescription266903",
    "clean_content": "Microscopic (histologic) description\n\n* Splenic white pulp is prominent, with focal germinal centers and hyperplastic marginal zones* Red pulp is cellular with histiocytes, activated lymphocytes (immunoblasts) and neutrophils* Increased number of cordal macrophages, with phagocytosis of (apparent) antibody coated platelets* Cords of Billroth may have a dirty appearance due to granular platelet debris both within macrophages and extracellularly* Reference: [HemaSphere: The spleen in immune thrombocytopenia [Accessed 22 February 2021]](https://journals.lww.com/hemasphere/Citation/2018/06002/The_spleen_in_immune_thrombocytopenia.66.aspx)"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-15",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#microscopichistologicimages266904",
    "clean_content": "Microscopic (histologic) images\n\nContributed by Julia Geyer, M.D.  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/spleenITP_Geyer01.png)](https://www.pathologyoutlines.com/imgau/spleenITP_Geyer01.png)\n\nFocal germinal centers, hyperplastic marginal zones\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/spleenITP_Geyer02.png)](https://www.pathologyoutlines.com/imgau/spleenITP_Geyer02.png)\n\nHistiocytes, immunoblasts, neutrophils, macrophages\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/spleenITP_Geyer03.png)](https://www.pathologyoutlines.com/imgau/spleenITP_Geyer03.png)\n\nExpanded red pulp, atrophic white pulp\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/spleenITP_Geyer04.jpg)](https://www.pathologyoutlines.com/imgau/spleenITP_Geyer04.jpg)\n\nCordal macrophages, phagocytosing platelets"
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-16",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#samplepathologyreport266919",
    "clean_content": "Sample pathology report\n\n* ITP is a clinical diagnosis of exclusion, typically not based primarily on a pathology specimen."
  },
  {
    "id": "immune-thrombocytopenia-itp_36874_1750165658.txt-17",
    "source_document": "immune-thrombocytopenia-itp_36874_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/spleenITP.html#differentialdiagnosis266920",
    "clean_content": "Differential diagnosis\n\n* ITP is a diagnosis of exclusion; an isolated thrombocytopenia is present (peripheral blood platelet count < 100 × 109/L) without anemia or leukopenia and without another apparent cause of thrombocytopenia such as:\n  + [Drug induced thrombocytopenia](https://www.pathologyoutlines.com/topic/coagulationacquiredhypercoaggeneral.html), including [heparin induced thrombocytopenia](https://www.pathologyoutlines.com/topic/coagulationheparininducedthrombocytopenia.html)+ **Infections+ Liver disease** and [hypersplenism](https://www.pathologyoutlines.com/topic/spleennonspecificabnormalfeatures.html#hypersplenism)+ **Microangiopathic processes**+ [Hereditary thrombocytopenia](https://www.pathologyoutlines.com/topic/coagulationhereditarybleedinggeneral.html)+ [Myelodysplastic syndromes](https://www.pathologyoutlines.com/topic/bonemarrowneoplasticMDSWHO.html) and other acquired bone marrow disorders"
  }
]